Pharma Icebreaker Panel Discussion:
- Comparing sentiment towards immunology deal-making. Which stage of development is most appealing?
- What are the starting points, from a data package perspective, when it comes to assessing engagers or in vivo CAR-T? When evaluating an early-stage what level of data—whether safety, biomarkers, or efficacy—provides you with conviction that the program has true drug potential?
- Which diseases do you think are most promising for B-cell targeted therapies?